Dori Thomas-Karyat
Company: Synthis LLC
Job title: CEO
Seminars:
Analyzing How SYN101, an Immune Cell Targeted TGF-β Inhibitor, Selectively Blocks Immune Suppression & Restores Tumor Clearance In Vitro & In Vivo 1:30 pm
Highlighting TGF-β is one of the most immunosuppressive cytokines in cancers Illuminating SYN-101 as a first-in-class, ADC-like molecule that selectively blocks TGF-β mediated immune suppression for cancer patients Accentuating that selective blockade of TGF-β signalling in immune cells restores immune function and drives tumor clearance in vivoRead more
day: Day Two